Lv5
929 积分 2021-05-16 加入
Orally bioavailable Syk inhibitors with activity in a rat PK/PD model
2天前
已完结
Prevention of the Drug Resistance of Helicobacter pylori with 8-Octyl Berberine by Increasing Membrane Permeability and Reducing Motility
19天前
已完结
Abstract LB218: Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
28天前
已完结
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
28天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
29天前
已完结
RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)
29天前
已完结
Development of a Scalable Manufacturing Synthesis for Enarodustat
1个月前
已完结
Prodrug approaches for the development of a long-acting drug delivery systems
1个月前
已完结
Binary lipid system-based granules with undissolved drug crystals enhance oral bioavailability by preventing degradation and improving permeability
1个月前
已完结
皖公网安备34019202002308
